Does Blue Cross Blue Shield Cover Forteo?

What Is Forteo and Why Does BCBS Scrutinize It So Closely?

Forteo is a recombinant form of human parathyroid hormone (PTH 1-34) approved by the FDA in 2002 for osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and patients on long-term glucocorticoid therapy. Unlike bisphosphonates, which slow bone breakdown, teriparatide stimulates new bone formation. That anabolic mechanism produces larger fracture-risk reductions but also carries a much higher price tag, which is exactly why BCBS medical-policy teams place it behind strict coverage criteria.

Clinical Efficacy That Justifies the Cost Argument

The key fracture-prevention trial for teriparatide enrolled 1,637 postmenopausal women with prior vertebral fractures. After a median of 21 months, teriparatide reduced new vertebral fractures by 65 percent and non-vertebral fragility fractures by 53 percent compared to placebo (Neer et al., NEJM 2001) [1]. Lumbar spine BMD rose by 9.7 percent and femoral neck BMD by 2.8 percent in the treatment arm.

A 2019 head-to-head trial (VERO, N=680) showed teriparatide reduced new vertebral fractures by 56 percent compared with risedronate over 24 months (Kendler et al., Lancet 2018) [2]. That direct superiority data is the clinical argument your physician can cite in a prior authorization letter.

The FDA Label Restriction That Drives Utilization Management

The FDA approved Forteo with a boxed warning about osteosarcoma risk observed in rat studies and mandated a lifetime treatment cap of 2 years. The FDA prescribing information for teriparatide states that the drug "is not recommended for patients who are at increased baseline risk for osteosarcoma" [3]. BCBS utilization management programs use this same 24-month limit as a hard stop in their coverage criteria, so re-authorization after 2 years is denied by policy, not by clinical judgment.

How BCBS Plans Structure Formulary Coverage for Forteo

BCBS is not a single insurer. It is a federation of 34 independent regional plans, each with its own formulary and medical policy. Despite that fragmentation, the clinical criteria across plans are strikingly similar because most rely on evidence-based guidelines from the American Association of Clinical Endocrinology (AACE) and the Endocrine Society.

Formulary Tier Placement

On the majority of BCBS commercial formularies, Forteo occupies Specialty Tier (Tier 4 or Tier 5). Specialty tiers carry the highest cost-sharing percentages, often 25 to 33 percent coinsurance rather than a flat copay. The FDA's Orange Book lists teriparatide as a reference-listed drug with no current AB-rated generic, meaning insurers cannot substitute a lower-cost equivalent automatically [4].

Standard Prior Authorization Clinical Criteria

Most BCBS regional plans publish their prior authorization (PA) criteria as standalone medical policy documents. The criteria that appear most consistently across plans include:

• A DXA scan showing a T-score at or below -2.5 at the spine, hip, or femoral neck, or a T-score at or below -2.0 with one or more fragility fractures
• Diagnosis confirmed by a physician as osteoporosis, not osteopenia alone
• Documented failure, contraindication, or intolerance to at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly are the most commonly specified agents)
• Prescriber is an endocrinologist, rheumatologist, or other specialist experienced in metabolic bone disease (some plans also accept primary care)
• Absence of conditions that increase osteosarcoma risk: Paget's disease, prior skeletal radiation, unexplained elevation of alkaline phosphatase

Step Therapy: What "Failure" Means in Practice

Step therapy for Forteo almost always requires bisphosphonate failure first. BCBS plans typically accept any of the following as evidence of failure:

1. Documented fracture while on adequate bisphosphonate therapy for at least 12 months
2. Loss of BMD of 5 percent or more at any measured skeletal site after 12 months of therapy
3. Intolerance documented by chart note (esophageal irritation, severe GI symptoms, inability to remain upright 30 minutes post-dose)
4. Contraindication such as creatinine clearance below 35 mL/min, which is the threshold cited in bisphosphonate prescribing guidelines [5]

Prior Authorization: Step-by-Step Process

The PA process for Forteo under a BCBS plan generally follows the same sequence regardless of which regional plan covers the patient.

Step 1: Confirm the Specific BCBS Plan's Drug Policy

Call the member services number on the back of the insurance card and ask for the "pharmacy prior authorization criteria for teriparatide (Forteo)." Request the full medical policy document number and effective date. Different BCBS affiliates, such as BCBS of Illinois, Anthem BCBS, or BCBS of North Carolina, maintain separate policies. Checking the National Drug Code (NDC) 00002-8476-01 (the pen injector) against the plan's specialty drug list confirms whether a PA is required before submitting.

Step 2: Gather Required Clinical Documentation

Your prescriber's office will need:

• Most recent DXA report with T-scores at all measured sites and the scan date
• Fracture history documentation from radiology or clinic notes
• Chart notes showing at least 12 months of bisphosphonate trial with dates, doses, and reason for discontinuation or failure
• Diagnosis codes: M81.0 (age-related osteoporosis without fracture) or M80.0x (osteoporosis with current pathological fracture)
• Laboratory results: serum calcium, 25-hydroxyvitamin D, creatinine, alkaline phosphatase

The National Osteoporosis Foundation clinical practice guide specifies that treatment should be initiated when the 10-year hip fracture probability exceeds 3 percent or major osteoporotic fracture probability exceeds 20 percent by FRAX [6]. Including the FRAX score in the PA submission strengthens the clinical narrative.

Step 3: Submit and Track the PA Request

Most BCBS plans accept PA submissions through CoverMyMeds, the Surescripts network, or direct fax to the pharmacy management vendor (typically CVS Caremark, Express Scripts, or Prime Therapeutics). The AMA's prior authorization reform guidelines recommend tracking the submission confirmation number and following up within 72 hours. Under the CMS interoperability rule for payers, commercial BCBS plans are required to respond to standard prior authorization requests within 72 hours for urgent cases and 7 days for standard requests, though individual state laws may shorten those windows.

Step 4: Approval, Denial, and the Appeal Path

If the PA is approved, BCBS will issue an authorization number and specify the approval period (typically 6 months with renewal). If denied, the denial letter must state the specific reason and include instructions for appeal. The BCBS Association's member rights documentation outlines the internal appeal process, which generally allows a first-level internal appeal within 60 days of denial, followed by an independent external review if the internal appeal fails [7].

Appealing a BCBS Denial for Forteo

Denials are common on the first submission. They do not mean Forteo is permanently unavailable.

Most Common Denial Reasons

Based on BCBS published medical policy language and common utilization management patterns, the most frequent denial reasons are:

• Insufficient documentation of bisphosphonate step therapy (the most common)
• T-score above the plan's threshold (T-score higher than -2.5 with no fracture history)
• Prescriber does not meet the plan's specialty requirement
• Missing DXA scan or scan older than 24 months

Writing a Strong Appeal Letter

An effective appeal letter should cite the specific clinical trial data directly. Referencing the VERO trial's 56 percent vertebral fracture reduction versus risedronate [2] or the Endocrine Society Clinical Practice Guideline for osteoporosis [5] gives the medical reviewer a published, peer-reviewed basis to overturn the denial.

The HealthRX Forteo Appeal Framework uses three parallel evidence layers:

1. Fracture risk quantification. Provide the FRAX 10-year probability score. The AACE 2020 guidelines classify patients with a 10-year major fracture risk above 20 percent as "high risk," for whom anabolic therapy is recommended first-line (AACE 2020 osteoporosis guidelines) [8].
2. Step therapy failure documentation. Attach pharmacy records with fill dates, prescriber notes describing the adverse effect or fracture, and any BMD change data.
3. Clinical guideline alignment. Quote the Endocrine Society's 2019 guideline: "For patients with very high fracture risk, anabolic therapy should be used as initial treatment." [5] That direct guideline language makes it difficult for a plan reviewer to uphold a denial based on step therapy when the patient meets the "very high risk" threshold.

External Review and State Insurance Commission Complaints

If the internal appeal fails, patients have the right to an independent external review under the Affordable Care Act. External reviewers overturn insurer denials in roughly 40 to 50 percent of specialty drug cases, according to data compiled by the Kaiser Family Foundation. Filing a complaint with the state insurance commissioner in parallel with the external review adds administrative pressure. Most states require the insurer to respond within 45 days.

Cost and Financial Assistance Options

Even with coverage, Forteo's specialty-tier cost sharing can be significant.

What BCBS Members Typically Pay

With specialty-tier coinsurance of 25 to 33 percent on a monthly supply priced at approximately $3,200 (AWP), out-of-pocket cost before hitting the deductible runs $800 to $1,050 per month. After meeting the annual deductible and out-of-pocket maximum, cost sharing drops significantly. The CMS drug spending dashboard confirms teriparatide as one of the highest per-beneficiary drug costs in Medicare Part D [9].

Eli Lilly Financial Assistance Programs

Eli Lilly operates two assistance pathways:

1. Lilly Insulin Value Program / Forteo co-pay card. Commercially insured patients may pay as little as $25 per month with the Lilly co-pay card. This card is not usable for government-insured patients (Medicare, Medicaid, TRICARE). Enrollment is available at the Lilly patient assistance portal, and eligibility is confirmed by calling 1-800-545-5979.
2. Lilly Cares Foundation. Uninsured or underinsured patients with household income at or below 400 percent of the federal poverty level may receive Forteo at no cost through this program. The Lilly Cares Foundation reviews applications within 10 business days.

Biosimilar and Generic Alternatives

The FDA has approved one biosimilar to Forteo: Tymlos (abaloparatide), a different peptide with a similar mechanism. Abaloparatide 80 mcg/day was studied in the ACTIVE trial (N=2,463), which showed a 43 percent reduction in vertebral fractures over 18 months versus placebo (Miller et al., JAMA 2016) [10]. Some BCBS plans have placed abaloparatide on a lower specialty tier than teriparatide, making it a lower-cost alternative if the prescriber is willing to use either agent.

A true generic teriparatide is not currently available in the United States. The FDA Orange Book shows no AB-rated generic as of the most recent update [4].

Medicare and Medicaid BCBS Plans: Different Rules Apply

Many BCBS plans administer Medicare Advantage (Part C) and Medicaid managed care contracts. The coverage rules differ materially from commercial plans.

Medicare Advantage BCBS Plans

Under Medicare Advantage, Forteo is typically covered under Part D (prescription drug benefit), not Part B. The plan's formulary must comply with CMS Part D guidelines [11], which require that any Part D drug listed in a therapeutic category must be accessible to enrollees who meet clinical criteria. Medicare Advantage plans must cover all drugs in "protected classes," but osteoporosis treatments are not in a protected class, so formulary restrictions are permitted.

The Low Income Subsidy (LIS) program caps out-of-pocket costs for qualifying Medicare beneficiaries. In 2024, the LIS full-benefit cap for specialty drugs was set at $11.20 per month under the Extra Help program, per CMS LIS program data [12].

Medicaid BCBS Managed Care Plans

State Medicaid programs must cover all FDA-approved drugs under federal rebate agreements, but managed care organizations (MCOs) including BCBS Medicaid plans can still require PA. Medicaid PA criteria for teriparatide often mirror commercial criteria but may add income-based step therapy requirements. The Medicaid Drug Rebate Program guarantees manufacturer rebates that reduce net cost to the state, sometimes making approval easier than on a commercial plan [13].

Clinical Guidelines That Support Coverage Approval

Aligning the PA submission with published specialty guidelines gives BCBS medical reviewers a defensible clinical basis to approve.

AACE 2020 Osteoporosis Guidelines

The AACE 2020 Clinical Practice Guidelines for diagnosis and treatment of postmenopausal osteoporosis classify patients into three risk tiers: high, very high, and imminent fracture risk (Camacho et al., Endocrine Practice 2020) [8]. For "very high risk" patients (T-score below -3.0, multiple fractures, or fracture on antiresorptive therapy), the AACE recommends anabolic therapy such as teriparatide as preferred first-line treatment. Citing this guideline tier explicitly in a PA or appeal letter reframes the request from an exceptional use to a guideline-concordant standard of care.

Endocrine Society 2019 Clinical Practice Guideline

The Endocrine Society's guideline states: "For patients at very high risk of fracture, we suggest using an anabolic agent (teriparatide, abaloparatide, or romosozumab) rather than an antiresorptive agent as initial treatment." (Eastell et al., JCEM 2019) [5]. That language directly addresses the step therapy requirement by identifying a clinical population for whom skipping bisphosphonate step therapy is appropriate.

NOF Clinical Practice Guide

The National Osteoporosis Foundation recommends treatment for postmenopausal women and men age 50 and older with a hip or spine T-score at or below -2.5, a prior hip or vertebral fracture, or a FRAX score exceeding the intervention thresholds (Cosman et al., Osteoporos Int 2014) [14]. DXA scans should be performed using ISCD-accredited facilities to ensure measurement precision and reproducibility [15]. Submitting both FRAX and DXA data together provides a quantitative fracture risk profile that is harder for a BCBS reviewer to dismiss.

ACR 2022 Glucocorticoid-Induced Osteoporosis Guidelines

Patients on long-term glucocorticoid therapy represent a distinct BCBS coverage scenario. The ACR 2022 guideline for glucocorticoid-induced osteoporosis [16] recommends teriparatide for patients at high fracture risk taking prednisone 7.5 mg/day or more for 3 months or longer. For this indication, some BCBS plans waive bisphosphonate step therapy entirely because the ACR guideline recommends anabolic therapy without requiring prior bisphosphonate failure.

Monitoring Requirements During Forteo Therapy

Coverage approval for subsequent authorization periods typically requires documented clinical response. BCBS plans increasingly require proof of efficacy at renewal.

Required Monitoring Tests

The Endocrine Society monitoring recommendations [5] for patients on teriparatide include:

• Serum calcium measured 1 month after initiation (teriparatide causes transient hypercalcemia in about 11 percent of patients per the FDA label)
• DXA at the lumbar spine and hip at 12 to 18 months (some BCBS plans require a DXA at 12 months for renewal authorization)
• Biochemical markers of bone turnover: procollagen type 1 N-terminal propeptide (P1NP) at 1 and 3 months confirms anabolic response (Vasikaran et al., Osteoporos Int 2011) [17]
• Serum 25-hydroxyvitamin D should be at or above 30 ng/mL before initiation per Endocrine Society vitamin D guidelines [18]

Transition Therapy After Forteo Completion

After 2 years of teriparatide, the FDA label and clinical guidelines both recommend transitioning to antiresorptive therapy to maintain the BMD gains. The IDENTITY trial showed that stopping teriparatide without follow-on antiresorptive therapy results in significant BMD loss within 30 months [19]. BCBS plans may require documentation of a planned transition agent (typically denosumab or a bisphosphonate) when renewing the second year of teriparatide authorization.

Practical Tips for Getting BCBS to Approve Forteo

A brief summary of actions that consistently improve approval rates:

• Submit the DXA report, fracture history, FRAX calculation, bisphosphonate trial records, and the AACE or Endocrine Society guideline page all in one fax. Incomplete submissions are the single most correctable denial cause.
• Have the prescriber annotate the FRAX score as "very high risk" using AACE 2020 language before sending, not after denial.
• Request peer-to-peer review if the PA is denied. A 15-minute call between the prescribing physician and the BCBS medical director resolves many denials that would otherwise require a formal appeal.
• Check whether the BCBS plan covers Forteo under the medical benefit (billed as a physician-administered injectable) rather than the pharmacy benefit. Some plans have lower cost-sharing for physician-office-administered specialty drugs.
• If the plan requires 12 months of bisphosphonate failure and the patient has only 6 months documented, ask the physician to extend the bisphosphonate trial with increased monitoring and re-submit at 12 months with the complete record.

For patients at very high fracture risk where a 12-month delay poses genuine harm, cite the Endocrine Society's guideline language on anabolic-first therapy [5] and request a medical necessity exception in writing, addressed directly to the BCBS Chief Medical Officer rather than the standard PA department.

At the HealthRX clinical intake, patients requesting Forteo authorization are asked to confirm their most recent DXA T-score and FRAX major osteoporotic fracture percentage before the PA is submitted. Submitting an incomplete packet is the single most avoidable reason for a first-cycle denial.